Stock Watch: Novartis Earnings Get Interesting Boost
How Interest Rate Rises Help Prop Pharma Profits
Executive Summary
A number of facets from last quarter’s earnings season carried over to Novartis’s first-quarter report, including pipeline attrition and the dependence of sales growth on a single product. While new, still minor products are hoped eventually to buffer its patent expiries, help from another corner has emerged.
You may also be interested in...
ANDA Sponsors Knock Out Key US Entresto Patent, Mylan Falls To Infringement
Entresto, one of the major small molecule opportunities for ANDA sponsors in the US, has seen a key patent knocked out following a challenge by generics manufacturers.
Stock Watch: Queasiness After The Humira Banquet
The second week of first-quarter earnings featured AbbVie’s announcement and a harsh stock price reaction. There were also far-reaching implications behind the results.
Vaccines Helped GSK Post Strong Q1 Results Ahead Of RSV Approval
Increased disease awareness and the IRA should help boost the RSV prevention market for older adults, said GSK CEO Emma Walmsley, ahead of a US approval decision early next month, as the firm’s vaccines division helped push a strong Q1 performance. Other deals are also ‘in the hopper.’